Linkedin-in Facebook-f
Our Portfolio Companies
  • About Us
    • About Us
    • Staff and Board of Directors
  • Industry & Investors
    • Partnership Models
    • Venture Funds
  • Success Stories
  • Media Center
    • News
    • Podcasts
    • Press Releases
  • Faculty & Researchers
    • Courses
  • Contact Us
Menu
  • About Us
    • About Us
    • Staff and Board of Directors
  • Industry & Investors
    • Partnership Models
    • Venture Funds
  • Success Stories
  • Media Center
    • News
    • Podcasts
    • Press Releases
  • Faculty & Researchers
    • Courses
  • Contact Us
Briefcase Loading...

No. 9740

Add to Briefcase

Enhancing Oral Bioavailability of Cannabinoids

CategoryProlonged release oral tablets   
KeywordsCannabinoids, Cannabis, tablets, oral administration

 

Application

In recent years, the medical use of cannabis and its derivatives has become widely accepted in the medical profession.  IN addition, policy changes throughout many countries now allow for cannabis to be prescribed for medicinal purposes. For reasons of patient compliance as well as to control the side effects, there is a rising need for an oral controlled release cannabinoid formulation. Cannabinoids, however, are not candidates for classical controlled release delivery systems, because the extremely lipophilic characteristics of THC and CBD limit their absorption along the intestine.

Our Innovation

We suggest a novel solid dosage form that enables the controlled release of cannabinoids by using gastro retentive tablets. These formulations are designed sit in the stomach for a prolonged period of time, allowing the release of their drug load in a continuous manner. Subsequently, the patient will retain prolonged active blood levels that lead to benefits such as:

  • Fewer side effects associated with the peaks and lows of IR formulations
  • Superior patient compliance

Opportunity

The proposed Gastro-Retentive Tablets are a platform technology relevant for various therapeutic indications. They offer the advantage of oral administration along with both a controlled and prolonged release of cannabinoids.

PATENT STATUS

Published WO 2021/137225

Lead Researcher

Prof. Amnon Hoffman

School of Pharmacy- Institute for Drug Research

Business Development Person

Ariela Markel VP, BD, Healthcare Contact

Category

  • Pharmaceuticals
ADDRESS

Hi-Tech Park, Edmond J. Safra
Campus, Bungalow 2.6
Givat-Ram, Jerusalem
P.O. Box 39135
91390 Israel

CONTACT US
  • Phone: +972-2-658-6688
  • Fax: +972-2-658-6689
  • Email: [email protected]
FOLLOW US
Twitter Linkedin-in Facebook-f Youtube
COPYRIGHT
Twitter Linkedin-in Facebook-f Youtube
  • About Us
    • About Us
    • Staff and Board of Directors
  • Industry & Investors
    • Partnership Models
    • Venture Funds
  • Success Stories
  • Media Center
    • News
    • Podcasts
    • Press Releases
  • Faculty & Researchers
    • Courses
  • Contact Us
Search Our Technologies
Find a Research Expert
Our Portfolio Companies
Briefcase Loading...